Breaking News, Collaborations & Alliances

Ortho Biotech, NCI Enter Cancer R&D Pact

Ortho Biotech Oncology R&D, a unit of Centocor R&D, Inc., has entered into a five-year Cooperative R&D Agreement (CRADA) with the National Cancer Institute (NCI) to research and develop new cell therapy technologies as potential cancer treatments.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Ortho Biotech Oncology R&D, a unit of Centocor R&D, Inc., has entered into a five-year Cooperative R&D Agreement (CRADA) with the National Cancer Institute (NCI) to research and develop new cell therapy technologies as potential cancer treatments. Steven A. Rosenberg, M.D., Ph.D., chief, Surgery Branch, will serve as the NCI principal investigator. These adoptive immunotherapy technologies are designed to help the immune system fight cancer by seeking out and destroying cancerous tum...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters